PE20001333A1 - Proceso para estabilizar macrolidos de polieno - Google Patents

Proceso para estabilizar macrolidos de polieno

Info

Publication number
PE20001333A1
PE20001333A1 PE1999001209A PE00120999A PE20001333A1 PE 20001333 A1 PE20001333 A1 PE 20001333A1 PE 1999001209 A PE1999001209 A PE 1999001209A PE 00120999 A PE00120999 A PE 00120999A PE 20001333 A1 PE20001333 A1 PE 20001333A1
Authority
PE
Peru
Prior art keywords
stabilize
rapamycin
hydroxy
ethyl
refers
Prior art date
Application number
PE1999001209A
Other languages
English (en)
Spanish (es)
Inventor
Francois Navarro
Guy Stone
Samuel Petit
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26314797&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20001333(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20001333A1 publication Critical patent/PE20001333A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
PE1999001209A 1998-12-07 1999-12-03 Proceso para estabilizar macrolidos de polieno PE20001333A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9826882.4A GB9826882D0 (en) 1998-12-07 1998-12-07 Organic compounds
GBGB9904934.8A GB9904934D0 (en) 1998-12-07 1999-03-04 Organic compounds

Publications (1)

Publication Number Publication Date
PE20001333A1 true PE20001333A1 (es) 2000-12-12

Family

ID=26314797

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1999001209A PE20001333A1 (es) 1998-12-07 1999-12-03 Proceso para estabilizar macrolidos de polieno

Country Status (38)

Country Link
US (5) US6605613B2 (enExample)
EP (4) EP1743657A3 (enExample)
JP (3) JP3805625B2 (enExample)
KR (2) KR20060096477A (enExample)
CN (2) CN1261163C (enExample)
AR (3) AR026102A1 (enExample)
AT (1) ATE365051T1 (enExample)
AU (1) AU759219B2 (enExample)
BE (1) BE1012869A3 (enExample)
BR (1) BR9915986A (enExample)
CA (3) CA2651609A1 (enExample)
CO (1) CO4980847A1 (enExample)
CY (1) CY1106870T1 (enExample)
CZ (2) CZ303006B6 (enExample)
DE (1) DE69936352T3 (enExample)
DK (1) DK1137439T4 (enExample)
ES (1) ES2288033T5 (enExample)
FR (1) FR2786771B1 (enExample)
GB (2) GB9826882D0 (enExample)
HK (1) HK1038889B (enExample)
HU (2) HU228939B1 (enExample)
ID (1) ID29250A (enExample)
IL (1) IL143092A0 (enExample)
IT (1) IT1319701B1 (enExample)
MY (2) MY120594A (enExample)
NO (2) NO332698B1 (enExample)
NZ (2) NZ511936A (enExample)
PE (1) PE20001333A1 (enExample)
PL (2) PL208854B1 (enExample)
PT (1) PT1137439E (enExample)
RU (1) RU2243769C2 (enExample)
SG (1) SG151072A1 (enExample)
SI (1) SI1137439T2 (enExample)
SK (2) SK286688B6 (enExample)
TR (2) TR200101416T2 (enExample)
TW (2) TWI270550B (enExample)
WO (1) WO2000033878A2 (enExample)
ZA (1) ZA200104360B (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070032853A1 (en) 2002-03-27 2007-02-08 Hossainy Syed F 40-O-(2-hydroxy)ethyl-rapamycin coated stent
US7452692B2 (en) 2002-02-13 2008-11-18 Teva Gyógyszergyár Zártkörüen Müködö Részvénytársaság Method for extracting a macrolide from biomatter
CA2475383C (en) 2002-02-13 2009-12-22 Biogal Gyogyszergyar Rt. Method for extracting a macrolide from biomatter
KR101131794B1 (ko) 2002-07-30 2012-03-30 와이어쓰 엘엘씨 Ｃｃｉ-779 공용매 농축액, 비경구 ｃｃｉ-779 제형 및 비경구 ｃｃｉ-779 제형의 제조방법
KR20050114262A (ko) * 2003-03-31 2005-12-05 테바 기오기스제르갸르 레스즈베니타르사사그 마크로라이드의 결정화 및 정제
US20050118344A1 (en) 2003-12-01 2005-06-02 Pacetti Stephen D. Temperature controlled crimping
WO2005010015A1 (en) 2003-07-24 2005-02-03 Teva Gyogyszergyar Reszvenytarsasag Method of purifying macrolides
CA2539324A1 (en) 2003-09-18 2005-03-31 Macusight, Inc. Transscleral delivery
US9114198B2 (en) * 2003-11-19 2015-08-25 Advanced Cardiovascular Systems, Inc. Biologically beneficial coatings for implantable devices containing fluorinated polymers and methods for fabricating the same
JP2007520262A (ja) * 2003-12-10 2007-07-26 アクルックス・ディ・ディ・エス・プロプライエタリー・リミテッド 経皮または局所薬物輸送に伴う副作用の処置方法
US8551512B2 (en) * 2004-03-22 2013-10-08 Advanced Cardiovascular Systems, Inc. Polyethylene glycol/poly(butylene terephthalate) copolymer coated devices including EVEROLIMUS
WO2006039237A1 (en) * 2004-09-29 2006-04-13 Cordis Corporation Pharmaceutical dosage forms of stable amorphous rapamycin like compounds
BRPI0607606B1 (pt) 2005-02-09 2021-06-22 Santen Pharmaceutical, Co., Ltd. Formulação líquida
AR058283A1 (es) * 2005-12-07 2008-01-30 Wyeth Corp Metodos para la preparacion de rapamicina cristalina y para la medicion de la cristalinidad de los compuestos de rapamicina utilizando calorimetria diferencial de barrido
US7700614B2 (en) * 2005-12-14 2010-04-20 Abbott Laboratories One pot synthesis of tetrazole derivatives of rapamycin
JP2009520818A (ja) * 2005-12-20 2009-05-28 ワイス 薬物物質不純物の制御によるｃｃｉ−７７９製剤安定性の制御
CN101605529B (zh) * 2006-02-09 2013-03-13 参天制药株式会社 稳定制剂及它们的制备和使用方法
BRPI0709016A2 (pt) 2006-03-23 2011-06-21 Macusight Inc formulações e métodos para doenças ou condições relacionadas com a permeabilidade vascular
AU2011260016B2 (en) 2010-06-02 2013-08-22 Fresenius Kabi Oncology Ltd. Stable pharmaceutical compositions of Rapamycin esters
WO2011156025A1 (en) * 2010-06-07 2011-12-15 Telik, Inc. Crystalline Ezatiostat Hydrochloride Ansolvate
US9321782B2 (en) * 2010-08-04 2016-04-26 Meril Life Sciences Pvt. Ltd. Process for preparation of novel 42-O-(heteroalkoxyalkyl) rapamicin compounds with anti-proliferative properties
WO2012066502A1 (en) 2010-11-19 2012-05-24 Biocon Limited Processes for preparation of everolimus and intermediates thereof
WO2012170384A1 (en) 2011-06-06 2012-12-13 Chevron Phillips Chemical Company Lp Use of metallocene compounds for cancer treatment
WO2013022201A1 (en) * 2011-08-11 2013-02-14 Dong-A Pharm. Co., Ltd. Process of preparing a stabilized and solubilized formulation of sirolimus derivatives
US9610385B2 (en) 2013-03-07 2017-04-04 Abbott Cardiovascular Systems Inc. Method of fabricating an implantable medical device comprising a rapamycin derivative
IN2013MU02532A (enExample) 2013-07-31 2015-06-26 Sahajanand Medical Technologies Pvt Ltd
CN104721158B (zh) * 2013-12-24 2018-01-30 正大天晴药业集团股份有限公司 一种稳定的依维莫司片剂
CN104892632B (zh) * 2015-06-03 2017-12-26 道中道（菏泽）制药有限公司 一种晶体形式的依维莫司及其制备方法
EP3329916A4 (en) 2015-07-28 2019-03-20 Nippon Kayaku Kabushiki Kaisha PHARMACEUTICAL COMPOSITION COMPRISING RAPAMYCIN OR A DERIVATIVE THEREOF, AND PROCESS FOR PRODUCING THE SAME
US20190015513A1 (en) * 2015-08-28 2019-01-17 Nippon Kayaku Kabushiki Kaisha Pharmaceutical composition comprising rapamycin or derivative thereof
WO2017047618A1 (ja) * 2015-09-18 2017-03-23 日本化薬株式会社 ラパマイシン又はその誘導体を含有する医薬組成物
WO2017129772A1 (en) 2016-01-29 2017-08-03 Xellia Phamaceuticals Aps Stable pharmaceutical compositions of temsirolimus
JP6855470B2 (ja) 2016-05-27 2021-04-07 日本化薬株式会社 ラパマイシン又はその誘導体を含有する医薬組成物
KR102051806B1 (ko) * 2018-01-12 2019-12-04 주식회사 종근당 에베로리무스를 포함하는 안정화된 약제학적 제제
EP4126882A1 (en) * 2020-03-27 2023-02-08 Boston Scientific Scimed Inc. Methods for crystallization of drugs
JP2023028473A (ja) * 2021-08-19 2023-03-03 日本マイクロバイオファーマ株式会社 エベロリムスの製造方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA737247B (en) * 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
US3996355A (en) 1975-01-02 1976-12-07 American Home Products Corporation Permanent suspension pharmaceutical dosage form
US4049128A (en) 1976-11-18 1977-09-20 Westinghouse Air Brake Company Control system for automatic railway car coupler
AU543727B2 (en) * 1980-06-02 1985-05-02 Ayerst Mckenna & Harrison Inc. Injectable composition of rapamycin
GB8803836D0 (en) 1988-02-18 1988-03-16 Glaxo Group Ltd Compositions
CA1338150C (en) † 1988-02-18 1996-03-12 Edward George Howard, Jr. Ceramic/distillable binder compositions
KR0159766B1 (ko) * 1989-10-16 1998-12-01 후지사와 토모키치로 양모제 조성물
JPH04230389A (ja) * 1990-07-16 1992-08-19 American Home Prod Corp ラパマイシン誘導体
FI97472C (fi) * 1991-05-07 1996-12-27 American Home Prod Menetelmä terapeuttisesti käyttökelpoisten rapamysiinijohdannaisten valmistamiseksi anti-inflammatorisina ja antifungaalisina aineina
GB9221220D0 (en) * 1992-10-09 1992-11-25 Sandoz Ag Organic componds
US5302584A (en) * 1992-10-13 1994-04-12 American Home Products Corporation Carbamates of rapamycin
EP1266900A1 (en) 1992-10-13 2002-12-18 Wyeth Carbamates of rapamycin
RU2181054C2 (ru) * 1994-11-02 2002-04-10 Новартис Аг Микроэмульсионный предконцентрат
ATE228135T1 (de) * 1995-06-09 2002-12-15 Novartis Erfind Verwalt Gmbh Rapamycinderivate
FR2736550B1 (fr) * 1995-07-14 1998-07-24 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule
EP1208847B8 (en) * 1996-07-30 2007-02-14 Novartis AG Pharmaceutical compositions for the treatment of transplant rejection, as well as autoimmune or inflammatory conditions
US6362264B1 (en) * 1996-12-20 2002-03-26 Ck Witco Corporation Stabilizer for food contact and medical grade PVC
JP2001511780A (ja) 1997-02-04 2001-08-14 アボツト・ラボラトリーズ 鎮痛性非経口リポソーム配合物

Also Published As

Publication number Publication date
US6852729B2 (en) 2005-02-08
TWI270550B (en) 2007-01-11
WO2000033878A3 (en) 2000-11-02
ES2288033T3 (es) 2007-12-16
KR20010101128A (ko) 2001-11-14
HK1038889B (en) 2008-01-25
CN1374872A (zh) 2002-10-16
US7741338B2 (en) 2010-06-22
DE69936352D1 (de) 2007-08-02
CA2651609A1 (en) 2000-06-15
US7572804B2 (en) 2009-08-11
US7297703B2 (en) 2007-11-20
SK287325B6 (sk) 2010-07-07
TWI248938B (en) 2006-02-11
JP5165199B2 (ja) 2013-03-21
EP1743657A2 (en) 2007-01-17
EP1137439B1 (en) 2007-06-20
SI1137439T2 (sl) 2012-05-31
PT1137439E (pt) 2007-09-25
KR20060096477A (ko) 2006-09-11
AR048073A2 (es) 2006-03-29
HU230174B1 (hu) 2015-09-28
EP1137439B2 (en) 2011-11-23
JP3805625B2 (ja) 2006-08-02
AR026102A1 (es) 2003-01-29
CA2351580C (en) 2012-03-20
JP2006111637A (ja) 2006-04-27
WO2000033878A2 (en) 2000-06-15
EP2269651A2 (en) 2011-01-05
JP2005200429A (ja) 2005-07-28
MY120594A (en) 2005-11-30
EP1743657A3 (en) 2007-03-28
US20050107418A1 (en) 2005-05-19
HUP0104489A2 (hu) 2002-03-28
US20020032213A1 (en) 2002-03-14
NZ527781A (en) 2004-11-26
FR2786771B1 (fr) 2002-12-27
NO20012424D0 (no) 2001-05-16
IT1319701B1 (it) 2003-10-27
CN1261163C (zh) 2006-06-28
ATE365051T1 (de) 2007-07-15
SK286688B6 (sk) 2009-03-05
CA2732620A1 (en) 2000-06-15
AU1657300A (en) 2000-06-26
DE69936352T2 (de) 2008-02-14
US20090270441A1 (en) 2009-10-29
ID29250A (id) 2001-08-16
GB9826882D0 (en) 1999-01-27
HUP0104489A3 (en) 2004-05-28
IL143092A0 (en) 2002-04-21
CN1876657B (zh) 2013-01-09
DE69936352T3 (de) 2012-05-03
HK1038889A1 (en) 2002-04-04
DK1137439T4 (da) 2012-03-19
PL208854B1 (pl) 2011-06-30
NO20121113L (no) 2001-05-16
ITMI992520A1 (it) 2001-06-02
AR054444A2 (es) 2007-06-27
CY1106870T1 (el) 2012-09-26
DK1137439T3 (da) 2007-09-10
HU228939B1 (en) 2013-07-29
EP1137439A2 (en) 2001-10-04
JP5043308B2 (ja) 2012-10-10
CZ20012001A3 (cs) 2001-09-12
NO332698B1 (no) 2012-12-10
US6605613B2 (en) 2003-08-12
NO334612B1 (no) 2014-04-22
CZ302210B6 (cs) 2010-12-22
PL348333A1 (en) 2002-05-20
PL196627B1 (pl) 2008-01-31
FR2786771A1 (fr) 2000-06-09
EP2279751A2 (en) 2011-02-02
ES2288033T5 (es) 2012-04-10
EP2269651A3 (en) 2011-03-09
US20080161334A1 (en) 2008-07-03
BR9915986A (pt) 2001-09-04
SI1137439T1 (sl) 2008-06-30
NZ511936A (en) 2003-10-31
TR200101416T2 (tr) 2002-01-21
SG151072A1 (en) 2009-06-29
KR100695834B1 (ko) 2007-03-19
MY127579A (en) 2006-12-29
CZ303006B6 (cs) 2012-02-22
SK7662001A3 (en) 2001-12-03
US20030191148A1 (en) 2003-10-09
CN1876657A (zh) 2006-12-13
GB9904934D0 (en) 1999-04-28
RU2243769C2 (ru) 2005-01-10
CA2732620C (en) 2013-08-06
BE1012869A3 (fr) 2001-04-03
NO20012424L (no) 2001-05-16
CO4980847A1 (es) 2000-11-27
ITMI992520A0 (it) 1999-12-02
TR200201428T2 (tr) 2002-12-23
CA2351580A1 (en) 2000-06-15
JP2002531527A (ja) 2002-09-24
TW200540179A (en) 2005-12-16
AU759219B2 (en) 2003-04-10
EP2279751A3 (en) 2011-02-16
ZA200104360B (en) 2002-01-16

Similar Documents

Publication Publication Date Title
PE20001333A1 (es) Proceso para estabilizar macrolidos de polieno
PE20221628A1 (es) Compuestos inhibidores de rip1 y metodos para hacer y utilizar los mismos
CY1113383T1 (el) Μεθοδος για την παρασκευη (αλφα s, βητα r)-6-βρωμο-αλφα-[2-(διμεθυλαμινο)αιθυλ]-2-μεθοξυ-αλφα-1-ναφθαλινυλ-βητα-φαινυλ-3-κινολινοαιθανολης
PE20050355A1 (es) Composiciones referidas a inhibidores de canales ionicos regulados por voltaje
GT200300292A (es) Derivados de pirimidina para el tratamiento de crecimiento celular anormal
CR8266A (es) Derivados de pirimidina para el tratamiento del crecimiento celular anormal
ECSP078060A (es) 2,4-diamino-pirimidinas como inhibidores de aurora
UY26962A1 (es) Monohidrato cristalino, procedimiento para su preparación y su utilización para la preparación de un medicamento
AR023071A1 (es) Compuestos de piridincetona, compuestos intermediarios, composicion herbicida e inhibidora del crecimiento de plantas, metodo para controlar la vegetacion indeseada, metodo para inhibir el crecimiento de las plantas, y uso de la composicion para controlar el crecimiento indeseado de plantas.
MXPA05009969A (es) Metodo para aislar la forma cristalina i de la 5-azacitidina.
PA8676201A1 (es) Metodos para sintetizar 3-cianoquinolinas sustituidad y sus intermediarios
ECSP066968A (es) Compuestos de metil-aril o heteroaril-amida sustituida
MX9400276A (es) Acidos hidroxamicos arilsulfonamido-sustituidos.
AR045134A1 (es) Compuesto de 1h - imidazo [4,5-c] piridin-ilo, composicion farmaceutica que lo comprende, proceso para prepararla, su uso para preparar dicha composicion farmaceutica, combinacion farmaceutica, uso de la combinacion farmaceutica para la preparacion de un medicamento, procedimientos para preparar dic
CR10095A (es) Derivados de pirimidina para el tratamiento del crecimiento celular anormal
IL162461A0 (en) Polymorphs of clopidogrel hydrogensulfate
ECSP078055A (es) Formas sólidas cristalinas de tigeciclina y métodos para preparar las mismas
BR9713261A (pt) Tricìclicos substituìdos
BRPI0413848B8 (pt) composto, processo para preparar o composto, composição terapêutica para prevenir inflamação e apoptose, processo para preparar a composição terapêutica e uso de composto, ou de seu sal, ou de seu estereoisômero
SI1572699T1 (sl) Kristalne soli cefdinira
AR001931A1 (es) Compuesto de 7-acilamino-3-iminometil (sustituido)cefalosporinas un proceso para su producción intermediarios en su producción una composición farmacéutica que contiene tales compuestos su utilizacióncomo compuestos farmacéuticos y un método para tratar enfermedades microbianas mediante administración de tales compuestos
BRPI0506858A (pt) composto, métodos de preparação de monoidrato de gaboxadol cristalino e de anidrato de gaboxadol cristalino, composição farmacêutica, e, uso de um composto
GT200100251A (es) Procedimiento para la preparacion de imidazotriazinonas substituidas con sulfonamida
MXPA05009688A (es) Derivados de naftiridina como agentes antibacterianos.
UY29343A1 (es) Pirazolopiridinas y sales de las mismas, una composición farmacéutica que comprende dichos compuestos, un método para prepararlos y su uso.

Legal Events

Date Code Title Description
FG Grant, registration
MK Expiration of term